Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 10 - 21 tags : Phase 3 save search
Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
MTNB | $0.1815 0.83% -0.61% 770K
|
Health Technology
|
| O: 0.0%
H: 4.39%
C: 2.63%
biopharma phase 1 potential drug iot phase 2 phase 3
SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
SCYX | $1.53 6.25% 5.88% 150K
|
Health Technology
|
| O: 0.95%
H: 3.58%
C: 2.83%
disease treatment infectious disease results phase 3 trial trial results injection infections
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Published: 2021-10-21 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.6%
H: 0.08%
C: -0.45%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.41%
C: 0.41%
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 2.66%
H: 3.69%
C: 3.53%
covid vaccine phase 3 trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.